RESUMEN
Objective:To study the incidence, clinical features, diagnosis, and treatment of angioimmunoblastic T-cell Lymphoma (AITL). Methods:We retrospectively analyzed the clinical data of 31 patients with AITL treated in the tumor hospital of Harbin Medical University between January 1995 and January 2008. We also analyzed the incidence, clinical features, diagnosis, and treatment of AITL. Results:The complete response rate and partial response rate of the entire group were 54.8%and 16.1%, respectively. The overall response rate was 70.9%, and the median survival time was 27.3 months. The five-year survival rate of the entire group was 35%. The response rate was 76.5%in the CHOP group and 75%in the COP group. No significant differences were detected between two groups (P>0.05). Con-clusion:The symptoms and signs of ATIL differ in different sites. The COP and CHOP regimens have similar efficacy and tolerable side effects.